Bayer AG has entered a global license and collaboration agreement with Kumquat Biosciences to develop and commercialize Kumquat's KRAS G12D inhibitor, a drug candidate targeting one of the most prevalent yet elusive oncogenic mutations in cancer. The deal, which could reach over $1.3 billion in payments, leverages Kumquat's recent IND clearance. Bayer will assume development and commercialization post-Phase Ia, focusing on pancreatic, colorectal, and lung cancers where KRAS G12D plays a significant role. This partnership reflects the expanding pursuit of targeted therapies for historically 'undruggable' mutations and complements Bayer's oncology portfolio.